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Abstract
Rationale: Smoking and inflammation contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD),
which involves changes in extracellular matrix. This is thought to contribute to airway remodeling and airflow obstruction.
We have previously observed that long-term treatment with inhaled corticosteroids can not only reduce bronchial
inflammation, but can also attenuate lung function decline in moderate-severe COPD. We hypothesized that inhaled
corticosteroids and current smoking modulate bronchial extracellular matrix components in COPD.
Objective: To compare major extracellular matrix components (elastic fibers; proteoglycans [versican, decorin]; collagens
type I and III) in bronchial biopsies 1) after 30-months inhaled steroids treatment or placebo; and 2) between current and ex-
smokers with COPD.
Methods: We included 64 moderate-severe, steroid-naive COPD patients (24/40 (ex)-smokers, 6267 years, 46 (31–54)
packyears, post-bronchodilator forced expiratory volume in one second (FEV1) 6269% predicted) at baseline in this
randomized, controlled trial. 19 and 13 patients received 30-months treatment with fluticasone or placebo, respectively.
Bronchial biopsies collected at baseline and after 30 months were studied using (immuno)histochemistry to evaluate
extracellular matrix content. Percentage and density of stained area were calculated by digital image analysis.
Results: 30-Months inhaled steroids increased the percentage stained area of versican (9.6% [CI 0.9 to 18.3%]; p = 0.03) and
collagen III (20.6% [CI 3.8 to 37.4%]; p = 0.02) compared to placebo. Increased collagen I staining density correlated with
increased post-bronchodilator FEV1 after inhaled steroids treatment (Rs = 0.45, p = 0.04). There were no differences between
smokers and ex-smokers with COPD in percentages and densities for all extracellular matrix proteins.
Conclusions: These data show that long-term inhaled corticosteroids treatment partially changes the composition of
extracellular matrix in moderate-severe COPD. This is associated with increased lung function, suggesting that long-term
inhaled steroids modulate airway remodeling thereby potentially preventing airway collapse in COPD. Smoking status is not
associated with bronchial extracellular matrix proteins.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is character-
ized by an abnormal inflammatory response and structural
alterations of the bronchial wall and parenchyma [1]. This
pulmonary remodeling has been linked to airflow limitation in
COPD [2,3]. Changes in the extracellular matrix (ECM),
produced by (myo)fibroblasts, epithelial cells and airway smooth
muscle cells, contribute to this remodeling process and alter airway
mechanics and dynamics [4,5]. The ECM consists of three major
components: elastic fibers, proteoglycans and collagens, which are
involved in cell migration, proliferation, adhesion, water balance
and regulation of inflammatory mediators [4].
The composition of the pulmonary ECM is different in subjects
with and without COPD. Fewer elastic fibers are found in small
airways and alveoli of COPD patients than in healthy controls
[6,7]. Furthermore, versican, a large proteoglycan is more
abundant, while the small proteoglycan decorin is reduced in
small airways in COPD compared to healthy subjects [8–10].
Collagens are the main component of the ECM, and collagen
composition differs between COPD patients and healthy controls
as shown by the observation that collagen type I is lower in the
large and small airways [11] and collagen type III expression is
lower in the small airways of COPD patients than in healthy
controls [3].
Since smoking is a risk factor for COPD, this may also influence
ECM composition. Indeed, cigarette smoke has been shown to
induce secretion of several profibrotic growth factors, including
transforming growth factor-beta (TGF-b), both in human lung
fibroblasts and in lung tissue of COPD patients [12,13]. Rodent
models exposed to cigarette smoke had less lung elastic fibers, but
more collagens than sham-smoked animals [14]. Others even
reported an increased elastic fibers gene expression in lung tissue
of severe COPD patients [15]. Smoke exposure decreased
proteoglycan expression as demonstrated by a study with
pulmonary fibroblasts from moderate and very severe COPD
patients [16].
Although generally (neutrophil dominated) inflammation in
COPD is considered to be resistant to steroids treatment, we
recently observed that long-term inhaled corticosteroids (ICS)
treatment partially decreased bronchial inflammation (CD3+,
CD4+, CD8+ and mast cells) -without effects on neutrophils- and
attenuated lung function decline in moderate-severe COPD
patients participating in the GLUCOLD (Groningen Leiden
Universities Corticosteroids in Obstructive Lung Disease) study
[17]. ICS may affect ECM through various mechanisms, including
modulation of inflammation by profibrotic mediators and target-
ing ECM genes directly. This may explain differences in the effects
of steroids that are observed in in vivo and in vitro studies. Whereas
steroid treatment of asthmatics did not change elastic fibers and
collagens in bronchial biopsies [18], steroids did inhibit serum-
induced proteoglycan production in fetal lung fibroblasts [19]. In
contrast to asthma, to the authors’ knowledge, effects of ICS on
ECM composition in COPD patients have not been described.
We hypothesized that inhaled steroids treatment modulates
bronchial ECM components in COPD. In addition, we hypoth-
esized that current smoking affects bronchial ECM.
Materials and Methods
Subjects and Study Design
The current study is a substudy of the GLUCOLD (Groningen
Leiden Universities Corticosteroids in Obstructive Lung Disease)
study, a double-blind, placebo-controlled randomized trial in
which 114 moderate-severe COPD steroid-naive patients were
included [17]. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. Clinically stable subjects
participating in the GLUCOLD study were aged 45–75 years,
smoked $10 packyears, were current or ex-smokers with $one
month of smoking cessation and were allowed to use short-acting
bronchodilators. Exclusion criteria were asthma and ICS use in
the previous 6 months. Patients were randomly assigned to receive
one of four treatments for 30 months: 1) fluticasone propionate
500 mg bid; 2) fluticasone/salmeterol 500/50 mg bid; 3) fluticasone
500 mg bid (6 months) and followed by placebo (24 months); or 4)
placebo bid. Diskus dry-powder inhalers (GlaxoSmithKline, Zeist,
The Netherlands), were used for inhalation of the study
medication and placebo, and both had equal appearance. For
the current study we used tissue and data of group 1 and 4.
Spirometry, reversibility to salbutamol and airway hyperreson-
siveness (PC20) were determined according to international
guidelines [20,21]. Approval of the medical ethics committees of
both centers was obtained: all subjects provided written informed
consent [17].
Bronchoscopy and Bronchial Biopsies
A fiberoptic bronchoscopy was performed at baseline and after
30 months according to standardized protocols [22]. Six bronchial
biopsies per patient per visit were collected at the 3rd–5th bronchial
level, one with the best morphology being used. Tissue of 64 out of
114 patients was available due to use in previous studies
[17,22,23].
(Immuno)Histochemical Stainings
Processing and analysis of bronchial biopsies was performed in
line with the recommendations of the ATS/ERS task force [24] by
using an internal reference parameter in the analysis. We did not
take specific precautions to orientate the samples during processing
to assure that the orientation of the biopsies is randomized [24].
However, since biopsies tend to curl after sampling, a random
orientation of the tissue structures is favored during embedding
[25]. Sections of 4 mm thickness of paraffin-embedded bronchial
biopsies were used for histochemistry (elastic fibers) and immuno-
histochemistry for proteoglycans and collagens. Elastic fibers were
stained according to Weigert’s protocol [26]. Versican, decorin,
collagen I and III antibodies were used after appropriate antigen
retrieval, followed by horseradish peroxidase-conjugated anti-
mouse or anti-rabbit EnVision system (DAKO, Glostrup, Den-
mark) and the chromogen NovaRed (Vector, Burlingame, CA).
Images of stained biopsies are presented in figure 1, and additional
information on the stainings is provided in table S1 in file S1.
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Digital Image Analysis
Tissue samples were analyzed in a blinded manner by
independent observers, unaware of the subjects’ clinical data
(LK, JS). Total biopsy images were acquired using a color camera
(2006magnification) and analyzed with image analysis software
(CellD, Olympus, Zoeterwoude, The Netherlands). The lamina
propria was selected per biopsy (minimum area 0.09 mm2). The
percentage stained area for a specific ECM component was
calculated dividing the stained area by the total selected area
(volume fraction; used as an internal reference parameter; [24]).
Staining intensity was further analyzed by densitometry (weighted
mean per biopsy) and presented as gray value (black: gray
value = 0; white: gray value = 255). Only immunohistochemical
stainings can represent density, therefore density was not
calculated for elastic fibers. Additional information on digital
image analysis is provided in file S1.
Statistical Analysis
Only biopsies from compliant subjects using $70% of the
prescribed dose were analyzed (per-protocol analysis). Means with
standard deviations (SD) and 95% confidence intervals (CI) or
medians with interquartile range (IQR) are presented. Differences
between smokers and ex-smokers were explored using Mann-
Whitney tests. Paired and independent t-tests were used for
evaluating the effect of ICS on ECM proteins within and between
treatments, respectively. Correlations were analyzed using Spear-
man correlation coefficient (Rs). Statistical analysis was performed
Figure 1. Examples of (immuno)histochemical stainings. The same bronchial biopsy section is shown for the histochemical staining for elastic
fibers (A) and the immunohistochemical stainings for versican (B), decorin (C), collagen type I (D) and collagen type III (E). Original magnification
2006.
doi:10.1371/journal.pone.0063430.g001
Table 1. Patient characteristics at baseline.
Smokers
(n =40) Ex-smokers (n =24)
Placebo
(n =13) Fluticasone (n =19)
Males [n (%)] 37 (92.5) 23 (95.8) 12 (92.3) 17 (89.5)
Age (years) 60.9 (7.2) 65.1 (6.6)* 62.5 (7.9) 62.0 (7.4)
Current/ex-smoker (n) 9/4 11/8
Packyears 46.8 (30.9–55.0) 37.5 (32.1–52.5) 42.0 (28.4–58.0) 44.9 (31.2–51.0)
Smoking cessation (years) 5.5 (1.3–10.0) 0.0 (0.0–1.5) 0.0 (0.0–5.0)
FEV1 post-bronchodilator (l) 2.05 (0.44) 1.94 (0.46) 1.95 (0.61) 2.03 (0.42)
FEV1 post-bronchodilator (%pred) 63.0 (8.7) 59.6 (9.9) 59.9 (9.8) 62.5 (9.5)
FEV1/IVC% post-bronchodilator 48.7 (8.9) 44.2 (8.9) 44.3 (9.5) 47.7 (8.6)
Geometric mean methacholine PC20 (mg/ml) 0.76 (2.9) 0.39 (3.0) 0.67 (1.9) 0.41 (2.4)
Patient characteristics for current smokers and ex-smokers with COPD and groups treated with placebo and fluticasone (only compliant patients). Bronchial biopsies
were available at baseline of 64 (elastic fibers), 56 (versican), 61 (decorin), 61 (collagen I) and 64 (collagen III) patients. After 30 months, bronchial biopsies of 32
compliant patients were available, tissue from 29 (elastic fibers), 26 (versican), 27 (decorin), 28 (collagen I) and 28 (collagen III) patients had sufficient surface area for
analysis ($0.09 mm2) (fluticasone and placebo groups combined). Data are presented as mean (SD) or median (IQR), unless otherwise stated. Methacholine PC20:
provocative concentration of methacholine that causes a 20% decrease in FEV1, expressed as mean doubling doses. Part of the data have been published previously
[17,22,27].
*p,0.05 compared to current smokers (two tailed unpaired t-tests).
doi:10.1371/journal.pone.0063430.t001
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with SPSS 17.0 software (SPSS Inc., Chicago, IL). Significance
was inferred at P#0.05.
Results
Patient Characteristics
At baseline, bronchial biopsies of 64 of 114 unselected
moderate-severe COPD patients [24/40 (ex-)smokers] were
included. A flow diagram of our study is presented in the figure
S1. Patient characteristics of the whole group have previously been
published [17,22,27]. 33 Patients were treated with either
fluticasone or placebo for 30 months (19/19 and 13/14 adherent
in fluticasone and placebo group, respectively). Mean post-
bronchodilator FEV1 was 62% predicted (SD 9.9%). Ex-smokers
were older at baseline compared to current smokers, as is shown in
table 1. Baseline characteristics of the entire group, groups with
available and unavailable bronchial biopsies, and the number of
available biopsies were not significantly different between both
treatment arms. During the study, six patients changed their
smoking habits (balanced among groups).
Figure 2. Percentage and density of stained area for placebo and fluticasone for all ECM proteins. Percentage (upper panel) and density
(lower panel) of stained area in bronchial biopsies is presented. Open figures: baseline percentage stained area, closed figures: percentage stained
area after 30 months. Horizontal bars represent medians.
doi:10.1371/journal.pone.0063430.g002
Figure 3. Correlation between change in post-bronchodilator
FEV1 (L) and change in density of collagen I. Both values
represent values after 30 months minus values at baseline. Closed
circles represent fluticasone treated subjects, open circles represent
placebo treated subjects.
doi:10.1371/journal.pone.0063430.g003
Long-Term Steroids and Airway Remodeling in COPD
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Inhaled Corticosteroids and Extracellular Matrix Proteins
Adjusted for baseline values, we found that ICS significantly
increased percentage versican (9.6% [CI 0.9 to 18.3%]; p= 0.03)
and collagen III (20.6% [CI 3.8 to 37.4%]; p = 0.02) compared to
placebo (figure 2); a trend was seen for the density of decorin (3.9
[CI 20.7 to 8.6]; p = 0.09) and collagen III (8.4 [CI21.1 to 17.9];
p = 0.09). Baseline percentage and density of versican (17% [CI
3.5 to 30.6%]; p = 0.02 and 8.0 [CI 2.7 to 13.3]; p = 0.006,
respectively) and collagen III (10.7% [0.1 to 21.4%]; p = 0.03 and
7.9 [CI 0.9 to 15.0]; p = 0.05, respectively) and percentage of
decorin (2.0% [CI 0.5 to 3.5%]; p = 0.02) were significantly higher
in the placebo group than the fluticasone group. Change in
smoking status was not included into our analysis, because current
and ex-smokers with COPD had similar ECM composition. An
increase in density of collagen I was associated with improvements
in post-bronchodilator FEV1 (l) (Rs = 0.45, P = 0.037) when we
Figure 4. Percentage and density of stained area at baseline of ex-smokers and smokers with COPD. Percentage (upper panel) and
density (lower panel) of stained area in bronchial biopsies is presented. Ex-smokers are presented as open circles, current smokers as closed circles.
Horizontal bars represent medians. No significant differences were found for all studied extracellular matrix proteins (both percentage stained area
and density).
doi:10.1371/journal.pone.0063430.g004
Figure 5. Correlation between percentage collagen type I at baseline and lung function parameters. Panel A presents post-
bronchodilator FEV1 (% predicted) and panel B shows PC20 (in doubling dose).
doi:10.1371/journal.pone.0063430.g005
Long-Term Steroids and Airway Remodeling in COPD
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analyzed both fluticasone and placebo treated groups combined
(figure 3). No correlations were found for other ECM proteins and
lung function.
Smoking Status and Extracellular Matrix Proteins at
Baseline
No significant differences in percentage of the area being
positively stained and density of ECM proteins were found
between current smokers and former smokers with COPD
(figure 4). Long-term ex-smokers ($5.5 years, our median value)
had similar percentage and density of all ECM proteins compared
to short term ex-smokers (,5.5 years) and current smokers (all
P.0.05). Furthermore, no relation was found between packyears
and percentage or density of all ECM proteins.
Correlations between Extracellular Matrix and Lung
Function at Baseline
Percentage collagen I correlated positively with FEV1 (%
predicted) post-bronchodilator (Rs = 0.31, P= 0.015) (figure 5, left
panel) and FEV1/IVC% (Rs= 0.38, P= 0.003). In addition,
percentage collagen type I and III correlated with PC20
(Rs = 0.33, P= 0.012; Rs= 0.37, P = 0.004, respectively) (figure 5,
right panel). Percentage collagen I, but not collagen III, was
significantly lower in GOLD stage III (n = 9) than GOLD stage II
(n = 55) (medians 5.5% and 17.7%, respectively, P= 0.01). No
significant correlations were found between lung function at
baseline and densities of all ECM proteins.
Discussion
Our results show that 30-month treatment with inhaled
corticosteroids increases the percentage stained area of versican
and collagen III, indicating that long-term treatment possibly
influences the remodeling process in the airways. Furthermore,
lung function is weakly, but positively correlated with collagen I
both at baseline and with regard to changes in FEV1 and collagen
I that occurred after treatment. In addition, we show that the
content of ECM proteins in bronchial biopsies did not significantly
differ between smokers and ex-smokers with moderate-severe
COPD.
This study shows that the content of elastic fibers, major
proteoglycans and collagens in the bronchial mucosa are similar in
current and ex-smokers with COPD. Our findings extend previous
observations, showing no difference in the percentage elastic fibers
in COPD patients and smokers without airway obstruction
[11,28]. We observed no significant difference in versican and
decorin content between current and ex-smokers with COPD,
which is in line with an in vitro study with cultured lung fibroblasts
of moderate COPD patients and control subjects. Cigarette smoke
extract (CSE) exposure of these cells did not affect versican gene
expression, but decreased decorin gene expression [16]. This
apparent difference with our findings could be explained by the
fact that smoke-exposed fibroblasts are only selectively triggered
compared to a multifactorial environment in vivo. Finally, in our
study collagen type I and III were not significantly different
between current and ex-smokers with COPD, which is similar to
recent observations in cultured fibroblasts of COPD and non-
COPD patients [29].
The percentage of versican and collagen III increased with long-
term ICS treatment compared to placebo, without significant
changes in elastic fibers, decorin and collagen I. In line with this,
ICS for four weeks or 3.5 years did not affect elastic fibers content
in bronchial biopsies of asthmatics compared to healthy controls
[18]. Notably, we found a significant increase in collagen III, but
not collagen I, after 2.5 years of ICS treatment compared to
placebo, which was associated with lung function. Previous studies
in COPD patients showed that gene expression of collagen 1a1
and collagen 3a1 in small airways and parenchyma was decreased
in association with lower FEV1 [3,30]. Thus, collagen may have
stabilizing effects on the collapsible airways in patients with
COPD, which could be further enhanced by long-term use of ICS.
Our study has various strong points. We included only steroid-
naive COPD patients, excluding possible influences of steroids on
ECM components at baseline. Both the percentage and density of
the stained area in bronchial biopsies were analyzed: the
percentage corresponds to the presence of the ECM protein,
whereas density represents the local amount of ECM protein. For
the analysis of the percentage, we used the total selected tissue area
for analysis as an internal reference parameter according to the
recommendations of the Joint ATS/ERS Task Force [24]. We
considered the possibility that part of our changes is explained by
an effect of ICS on edema. However, less edema resulting from
ICS treatment would probably have increased percentage and
density all studied ECM proteins, whereas in our study the
percentage of only some ECM proteins was affected. Furthermore,
we previously found lower numbers of selected bronchial
inflammatory cells after ICS treatment in the current study [17].
We did not find correlations between the effect of ICS treatment
on inflammatory cells and ECM components (data not shown).
There are some considerations when interpreting our results.
Matched bronchial biopsies both at baseline and follow-up were
available from approximately half of our COPD patients, because
part of the tissue was no longer available. This could have
negatively affected the power of our study. Still, the number of
available biopsies was similar among both groups. Furthermore,
since one biopsy per patient per visit was studied, we cannot
exclude that local heterogeneity of ECM proteins has affected our
results. To minimize selection bias, we only selected biopsies with
the largest lamina propria. Lung tissue specimens from healthy or
never-smokers were not available, but comparisons with these
groups were beyond the objectives of this study. Furthermore,
features of remodeling in COPD are different between large and
small airways, nevertheless we evaluated the ECM in the central
airways only [2] and important correlations with lung function
could still be observed. Finally, despite treatment randomization,
we accidentally found that the percentage and densities of
versican, decorin and collagen III at baseline were significantly
higher in the placebo than the fluticasone group. Not withstanding
this, when still adjusted for the baseline values, we observed effect
of ICS therapy. Taken together, we do not believe that the above
limitations largely affected our results.
How can we explain that smoking has no effect on ECM?
Exposure of cultured pulmonary fibroblasts of moderate and very
severe COPD patients to CSE resulted in downregulation of
decorin, but not versican and collagen type I and III expression
[16,29]. In addition, collagen I and tropoelastin were dose-
dependently inhibited by CSE in rat fetal lung fibroblasts [31].
Mice with long-term exposure to cigarette smoke showed a
decrease in elastic fibers and collagen type III, without significant
effect on collagen I [32]. We could only partially confirm these
in vitro and animal studies. Inflammation and remodeling in the
lung in vivo are simultaneous and complex ongoing processes and
may not be mimicked by studies in isolated fibroblasts and inbred
animals kept under specific conditions. Furthermore, after
smoking cessation bronchial inflammation (at least) partially
persists [22], which is in line with our finding of similar ECM
composition between smokers and ex-smokers.
Long-Term Steroids and Airway Remodeling in COPD
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We showed a positive correlation between the content of
collagen and lung function after treatment with inhaled steroids.
However, the current opinion of remodeling is that airway wall
thickening is strongly associated with progression of COPD [2],
suggesting that increased ECM deposition is related to a decreased
lung function. How can we explain this apparent contradiction? In
COPD, an imbalance between proteases and anti-proteases is
present, as shown by an excess of matrix metalloproteinases
(MMP) and a relative shortage of tissue inhibitor of metallopro-
teinases (TIMP) [33]. MMP degrade both collagens and proteo-
glycans [2,33,34]. Dexamethasone can reduce MMP-9 and
increase TIMP-1 release from alveolar macrophages of COPD
patients [35], which may result in a decreased capacity to degrade
ECM. This is in line with our observation that ICS increase
collagen and versican. Also the observation from Annoni et al [11],
showing that patients with COPD have lower collagen I densities
in their airways, is in line with the speculation that an increase in
collagen I induced by ICS could stabilize the airways. Further-
more, the observed positive correlation between collagen with lung
function and PC20 before and after long-term ICS therapy also
suggests that increased airway wall fibrosis is actually preventing
both airway collapse and attenuating airway smooth muscle
contractions in COPD. Besides airway remodeling, emphysema
might also influence airway collapse, which could contribute to the
airflow obstruction. Unfortunately, no data were collected to
quantify the extent of emphysema in our cohort of COPD
patients.
Although smoking cessation shows positive clinical effects [1],
smoking status was not significantly correlated with our studied
ECM components. Treatment with ICS increased the percentage
versican and collagen III. We found positive correlations between
ECM proteins and several lung function parameters at baseline
and after treatment with ICS. Therefore, our data may implicate
that steroids alter airway structure by increasing ECM content in
COPD which is associated with preserved lung function. This
suggests that increased presence ECM proteins do not by
themselves lead to detrimental consequences, but instead can
prevent airway collapse.
In conclusion, we showed that treatment for 30 months with
inhaled corticosteroids increased the relative content of versican
and collagen III in the large airways of patients with moderate to
severe COPD. Our data suggest that steroids not only prevent
bronchial inflammation but possibly also alter airway structure by
increasing specific ECM proteins in COPD that are associated
with improvements in lung function. Further studies are needed to
confirm these findings in other studies, and to understand the
possible implications of these findings for current treatment
strategies and for the development of future, targeted anti-
remodeling medication in COPD.
Supporting Information
Figure S1 Study flow diagram. Study flow diagram of the
GLUCOLD study presenting the bronchial biopsies used in this
study at baseline and after 30 months treatment with inhaled
fluticasone.
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